Evidence map›Paper›PMID 30526514›Full record

ArticleBMC infectious diseases2018

Seroprevalence of antibodies to primate erythroparvovirus 1 (B19V) in Australia.

Helen M Faddy, Elise C Gorman, Veronica C Hoad, Francesca D Frentiu, Sarah Tozer, R L P Flower

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Helen M FaddyResearch and Development, Australian Red Cross Blood Service, Brisbane, Queensland, Australia. hfaddy@redcrossblood.org.au.ORCID http://orcid.org/0000-0002-3446-8248
Elise C GormanResearch and Development, Australian Red Cross Blood Service, Brisbane, Queensland, Australia.
Veronica C HoadClinical Services and Research, Australian Red Cross Blood Service, Perth, Western Australia, Australia.
Francesca D FrentiuSchool of Biomedical Sciences, and Institute for Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
Sarah TozerQueensland Paediatric Infectious Diseases Laboratory, Centre for Children's Health Research, Brisbane, Queensland, Australia.
R L P FlowerResearch and Development, Australian Red Cross Blood Service, Brisbane, Queensland, Australia.
Queensland University of Technology · AUAustralian Red Cross Lifeblood · AUChildren's Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroudPrimate erythroparvovirus 1 (B19V) is a globally ubiquitous DNA virus. Infection results in a variety of clinical presentations including erythema infectiosum in children and arthralgia in adults. There is limited understanding of the seroprevalence of B19V antibodies in the Australian population and therefore of population-wide immunity. This study aimed to investigate the seroprevalence of B19V antibodies in an Australian blood donor cohort, along with a cohort from a paediatric population.

methodsAge/sex/geographical location stratified plasma samples (n = 2221) were collected from Australian blood donors. Samples were also sourced from paediatric patients (n = 223) in Queensland. All samples were screened for B19V IgG using an indirect- enzyme-linked immunosorbent assay.

resultsOverall, 57.90% (95% CI: 55.94%-59.85%) of samples tested positive for B19V IgG, with the national age-standardized seroprevalence of B19V exposure in Australians aged 0 to 79 years estimated to be 54.41%. Increasing age (p < 0.001) and state of residence (p < 0.001) were independently associated with B19V exposure in blood donors, with the highest rates in donors from Tasmania (71.88%, 95% CI: 66.95%-76.80%) and donors aged 65-80 years (78.41%, 95% CI: 74.11%-82.71%). A seroprevalence of 52.04% (95% CI: 47.92%-56.15%) was reported in women of child-bearing age (16 to 44 years). Sex was not associated with exposure in blood donors (p = 0.547) or in children (p = 0.261) screened in this study.

conclusionsThis study highlights a clear association between B19V exposure and increasing age, with over half of the Australian population likely to be immune to this virus. Differences in seroprevalence were also observed in donors residing in different states, with a higher prevalence reported in those from the southern states. The finding is consistent with previous studies, with higher rates observed in countries with a higher latitude. This study provides much needed insight into the prevalence of B19V exposure in the Australian population, which has implications for public health as well as transfusion and transplantation safety in Australia.

Indexed as

AdolescentAdultAgedAnimalsAntibodies, ViralAustraliaBlood DonorsChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleMiddle AgedParvoviridae InfectionsAntibodies, ViralAustraliaPaediatricParvovirus B19Public healthSeroprevalence

Identifiers

PMID30526514
PMCPMC6286569
OpenAlexW2905276013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.